Kevin G. Friedman

Kevin G. Friedman

Auto-generated profile, based on publicly available information

Kevin G. Friedman

Department of Cardiology Boston Children's Hospital Boston Massachusetts USA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 August 2020 in European Journal of Pediatrics
Verified
Journal Article
Open access
PDF file
FSFrancesca Sperotto
Francesca Sperotto
KFKevin G. Friedman
Kevin G. Friedman
MSMary Beth F. Son
Mary Beth F. Son
CVChristina J. VanderPluym
Christina J. VanderPluym
JNJane W. Newburger
Jane W. Newburger
ADAudrey Dionne
Audrey Dionne
Initial reports on COVID-19 described children as largely spared from severe manifestations, with only 2–6% of children requiring intensive care treatment. However, since mid-April 2020, clusters of pediatric cases of severe systemic hyperinflammation and shock epidemiologically linked with COVID-19 have been reported. This condition was named as SARS-Cov-2-associated multisystem inflammatory syndrome in children and showed similarities to Kawasaki disease. Here, we present a narrative review of cases reported in literature and we discuss the clinical acute and follow-up management of these patients. Patients with SARS-Cov-2-associated multisystem inflammatory syndrome frequently presented with persistent fever, gastrointestinal symptoms, polymorphic rash, conjunctivitis, and mucosal changes. Elevated inflammatory markers and evidence of cytokine storm were frequently observed. A subset of these patients also presented with hypotension and shock (20–100%) from either acute myocardial dysfunction or systemic hyperinflammation/vasodilation. Coronary artery dilation or aneurysms have been described in 6–24%, and arrhythmias in 7–60%. Cardiac support, immunomodulation, and anticoagulation are the key aspects for the management of the acute phase. Long-term structured follow-up of these patients is required due to the unclear prognosis and risk of progression of cardiac manifestations.Conclusion: Multisystem inflammatory syndrome is a novel syndrome related to SARS-CoV-2 infection. Evidence is still scarce but rapidly emerging in the literature. Cardiac manifestations are frequent, including myocardial and coronary involvement, and need to be carefully identified and monitored over time. What is Known:• Multisystem inflammatory syndrome in children (MIS-C) has been described associated with SARS-CoV-2.What is New:• Patients with MIS-C often present with fever, gastrointestinal symptoms, and shock.• Cardiac involvement is found in a high proportion of these patients, including ventricular dysfunction, coronary artery dilation or aneurysm, and arrhythmias.• Management is based on expert consensus and includes cardiac support, immunomodulatory agents, and anticoagulation.• Long-term follow-up is required due to the unclear prognosis and risk of progression of cardiac manifestation.

1 September 2016 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
KFKevin G. Friedman
Kevin G. Friedman
KGKimberly Gauvreau
Kimberly Gauvreau
AHAkiko Hamaoka‐Okamoto
Akiko Hamaoka‐Okamoto
ATAlexander Tang
Alexander Tang
EBErika Berry
Erika Berry
JNJane W. Newburger
Jane W. Newburger
Background: The natural history of coronary artery aneurysms ( CAA ) after intravenous immunoglobulin ( IVIG ) treatment in the United States is not well described. We describe the natural history of CAA in US Kawasaki disease ( KD ) patients and identify factors associated with major adverse cardiac events ( MACE ) and CAA regression. Methods and Results: We evaluated all KD patients with CAA at 2 centers from 1979 to 2014. Factors associated with CAA regression, maximum CA z ‐score over time ( z Max), and MACE were analyzed. We performed a matched analysis of treatment effect on likelihood of CAA regression. Of 2860 KD patients, 500 (17%) had CAA , including 90 with CAA z ‐score >10. Most (91%) received IVIG within 10 days of illness, 32% received >1 IVIG , and 27% received adjunctive anti‐inflammatory medications. CAA regression occurred in 75%. Lack of CAA regression and higher CAA z Max were associated with earlier era, larger CAA z ‐score at diagnosis, and bilateral CAA in univariate and multivariable analyses. MACE occurred in 24 (5%) patients and was associated with higher CAA z ‐score at diagnosis and lack of IVIG treatment. In a subset of patients (n=132) matched by age at KD and baseline CAA z ‐score, those receiving IVIG plus adjunctive medication had a CAA regression rate of 91% compared with 68% for the 3 other groups ( IVIG alone, IVIG ≥2 doses, or IVIG ≥2 doses plus adjunctive medication). Conclusions: CAA regression occurred in 75% of patients. CAA z ‐score at diagnosis was highly predictive of outcomes, which may be improved by early IVIG treatment and adjunctive therapies.

1 August 2011 in Pediatrics
Verified
Journal Article
Closed access
PDF file
KFKevin G. Friedman
Kevin G. Friedman
DKDavid A. Kane
David A. Kane
RRRahul H. Rathod
Rahul H. Rathod
ARAshley Renaud
Ashley Renaud
MFMichael Farias
Michael Farias
SSSusan F. Saleeb
Susan F. Saleeb
OBJECTIVES: Chest pain is a common reason for referral to pediatric cardiologists and often leads to an extensive cardiac evaluation. The objective of this study is to describe current management practices in the assessment of pediatric chest pain and to determine whether a standardized care approach could reduce unnecessary testing.PATIENTS AND METHODS: We reviewed all patients, aged 7 to 21 years, presenting to our outpatient pediatric cardiology division in 2009 for evaluation of chest pain. Demographics, clinical characteristics, patient outcomes, and resource use were analyzed.RESULTS: Testing included electrocardiography (ECG) in all 406 patients, echocardiography in 175 (43%), exercise stress testing in 114 (28%), event monitoring in 40 (10%), and Holter monitoring in 30 (7%). A total of 44 (11%) patients had a clinically significant medical or family history, an abnormal cardiac examination, and/or an abnormal ECG. Exertional chest pain was present in 150 (37%) patients. In the entire cohort, a cardiac etiology for chest pain was found in only 5 of 406 (1.2%) patients. Two patients had pericarditits, and 3 had arrhythmias. We developed an algorithm using pertinent history, physical examination, and ECG findings to suggest when additional testing is indicated. Applying the algorithm to this cohort could lead to an ∼20% reduction in echocardiogram and outpatient rhythm monitor use and elimination of exercise stress testing while still capturing all cardiac diagnoses.CONCLUSIONS: Evaluation of pediatric chest pain is often extensive and rarely yields a cardiac etiology. Practice variation and unnecessary resource use remain concerns. Targeted testing can reduce resource use and lead to more cost-effective care.

22 May 2017 in Ultrasound in Obstetrics & Gynecology
Verified
Journal Article
Open access
PDF file
KFK. G. Friedman
K. G. Friedman
LSL. A. Sleeper
L. A. Sleeper
LFL. R. Freud
L. R. Freud
AMA. C. Marshall
A. C. Marshall
MGM. E. Godfrey
M. E. Godfrey
WTW. Tworetzky
W. Tworetzky
Objectives: Fetal aortic valvuloplasty (FAV) may prevent progression of mid‐gestation aortic stenosis to hypoplastic left heart syndrome (HLHS). The aim of this study was to evaluate whether technical success and biventricular (Biv) outcome after FAV have changed from an earlier (2000–2008) to a more recent (2009–2015) era and identify pre‐FAV predictors of Biv outcome.Methods: We evaluated procedural and postnatal outcomes in 123 fetuses that underwent FAV for evolving HLHS at Boston Children's Hospital between 2000 and 2015. The primary outcome measure was circulation type (Biv vs single ventricle) at the time of neonatal hospital discharge. Classification and regression tree (CART) analysis was performed to construct a stratification algorithm to predict Biv circulation based on pre‐FAV fetal variables.Results: The FAV procedure was technically successful in 101/123 (82%) fetuses, with a higher technical success rate in the more recent era than in the earlier one (49/52 (94%) vs 52/71 (73%); P = 0.003). In liveborn patients, the incidence of Biv outcome was higher in the recent than in the earlier era, both in the entire liveborn cohort (29/49 (59%) vs 16/62 (26%); P = 0.001) and in those in whom the procedure was technically successful (27/46 (59%) vs 15/47 (32%); P = 0.007). Independent predictors of Biv outcome were higher left ventricular (LV) pressure, larger ascending aorta, better LV diastolic function and higher LV long‐axis Z‐score. On CART analysis, fetuses with LV pressure > 47 mmHg and ascending aorta Z‐score ≥ 0.57 had a 92% probability of Biv outcome (n = 24). Those with a lower LV pressure, or mitral dimension Z‐score < 0.1 and mitral valve inflow time Z‐score < –2 (n = 34) were unlikely to have Biv (probability of 9%). The remainder of the patients had an intermediate (∼40–60%) likelihood of Biv circulation.Conclusions: The proportion of patients achieving Biv outcome after FAV has increased, probably owing to an improved technical success rate and modified selection criteria. Fetal factors, including LV pressure, size of the ascending aorta and diastolic function, are associated with likelihood of Biv circulation after FAV. Copyright © 2017 ISUOG. Published by John Wiley & Sons Ltd.

1 September 2013 in The Journal of Pediatrics
Verified
Journal Article
Closed access
KFKevin G. Friedman
Kevin G. Friedman
MAMark E. Alexander
Mark E. Alexander

1 June 2019 in Pediatrics
Verified
Journal Article
Closed access
PDF file
ADAudrey Dionne
Audrey Dionne
JBJane C. Burns
Jane C. Burns
NDNagib Dahdah
Nagib Dahdah
ATAdriana H. Tremoulet
Adriana H. Tremoulet
KGKimberlee Gauvreau
Kimberlee Gauvreau
KFKevin G. Friedman
Kevin G. Friedman
BACKGROUND: Coronary artery aneurysms (CAA) are a serious complication of Kawasaki disease. Treatment with intravenous immunoglobulin (IVIg) within 10 days of fever onset reduces the risk of CAA from 25% to <5%. Corticosteroids and infliximab are often used in high-risk patients or those with CAA at diagnosis, but there are no data on their longer-term impact on CAA. METHODS: Retrospective multicenter study including children who had CAA with a z score ≥2.5 and <10 at time of diagnosis and who received primary therapy with IVIg alone or in combination with either corticosteroids or infliximab within 10 days of onset of fever. RESULTS: Of 121 children, with a median age of 2.8 (range 0.1–15.5) years, 30 (25%) received primary therapy with corticosteroids and IVIg, 58 (48%) received primary therapy with infliximab and IVIg, and 33 (27%) received primary therapy with IVIg only. Median coronary z scores at the time of diagnosis did not differ among treatment groups (P = .39). Primary treatment intensification with either corticosteroids or infliximab were independent protective factors against progression of coronary size on follow-up (coefficient: −1.31 [95% confidence interval: −2.33 to −0.29]; coefficient: −1.07 [95% confidence interval: −1.95 to −0.19], respectively). CONCLUSIONS: Among a high-risk group of patients with Kawasaki disease with CAA on baseline echocardiography, those treated with corticosteroids or infliximab in addition to IVIg had less progression in CAA size compared with those treated with IVIg alone. Prospective randomized trials are needed to determine the best adjunctive treatment of patients who present with CAA.